Patrick A. Plé

<i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Laurent Hennequin, J M Allen, J. Breed et al. · Journal of Medicinal Chemistry · 2006 · 367 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas et al. · Journal of Medicinal Chemistry · 2002 · 308 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker et al. · Molecular Oncology · 2009 · 256 citations · Full text

Medicine, Oncology, Pharmacology +10

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Andrew P. Thomas, Craig Johnstone et al. · Journal of Medicinal Chemistry · 1999 · 236 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Patrick A. Plé, Tim P. Green, Laurent Hennequin et al. · Journal of Medicinal Chemistry · 2004 · 167 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16